Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

• Status: Enrolling by invitation
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kadmon Corporation, LLC

Criteria

Inclusion Criteria:

Subjects must have been treated with belumosudil for at least 1 of the following:

• Actively receiving belumosudil on Study KD025-208 or Study KD025-213

• Is in Long-term Follow-up (LTFU) on Study KD025-208 or Study KD025-213. Long-term Follow-up will be defined as the period after ending treatment with belumosudil and until a FFS event occurs.

• Adult enrolled in the Companion Study under KD025-213 Amendment 2 (01 June 2020) and has received at least 6 months of treatment of belumosudil or is in LTFU

Exclusion Criteria:

• Female subject who is pregnant or breastfeeding

• Subject considered unlikely to adhere to treatment and/or follow protocol in the opinion of the Investigator